Improving Treatment Adherence in Your Patients with Schizophrenia

被引:41
作者
Canas, Fernando [1 ]
Alptekin, Koksal [2 ]
Azorin, Jean Michel [3 ]
Dubois, Vincent [4 ]
Emsley, Robin [5 ]
Garcia, Antonio G. [6 ]
Gorwood, Philip [7 ]
Haddad, Peter M. [8 ]
Naber, Dieter [9 ]
Olivares, Jose M. [10 ]
Papageorgiou, Georgios [11 ]
Roca, Miquel [12 ]
机构
[1] Hosp Dr Rodriguez Lafora, Dept Psychiat, Madrid 28049, Spain
[2] Dokuz Eylul Univ, Sch Med, Izmir, Turkey
[3] St Marguerite Hosp, Marseilles, France
[4] Clin Univ St Luc, B-1200 Brussels, Belgium
[5] Univ Stellenbosch, ZA-7505 Tygerberg, South Africa
[6] Univ Autonoma Madrid, Madrid, Spain
[7] Univ Paris 05, St Anne Hosp CMME, Paris, France
[8] Univ Manchester, Manchester, Lancs, England
[9] Univ Klinikum Hamburg Eppendorf, Hamburg, Germany
[10] Hosp Meixoeiro, Vigo, Spain
[11] Evangelismos Gen Hosp, Athens, Greece
[12] Inst Univ Invest Ciencies Salut, Hosp Juan March, Palma De Mallorca, Spain
关键词
ANTIPSYCHOTIC MEDICATION ADHERENCE; RANDOMIZED CONTROLLED-TRIAL; INDUCED WEIGHT-GAIN; THERAPEUTIC ALLIANCE; 1ST EPISODE; ATYPICAL ANTIPSYCHOTICS; FUNCTIONAL OUTCOMES; ORAL ANTIPSYCHOTICS; DOUBLE-BLIND; SELF-REPORT;
D O I
10.1007/s40261-012-0047-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Partial and non-adherence to medication is a common problem in schizophrenia, leading to an increased risk of relapse, increased likelihood of hospitalization and poorer long-term outcomes. In contrast, continuous medication in the treatment of schizophrenia is associated with positive outcomes, including improved clinical status, improved quality of life and functioning, and reduced risk of relapse and rehospitalization. Strategies aimed at improving medication adherence are therefore key for patients to achieve their treatment goals. In an attempt to address the issues of partial/non-adherence to antipsychotic medication in schizophrenia, a group of psychiatrists convened to discuss and develop a set of principles aimed at helping patients adhere to their medication. These principles were then refined and developed into the STAY (the Six principles to improve Treatment Adherence in Your patients) initiative following presentation to a wider group of psychiatrists from across Europe. This manuscript summarizes these principles and explains the rationale for their selection. These principles are: (1) recognizing that most patients with schizophrenia are at risk of partial/non-adherence at some time during the course of their illness; (2) the benefits of a good therapeutic alliance for identifying potential adherence issues; (3) tailored treatment plans to meet an individual's needs, including the most suitable route of delivery of antipsychotic medication; (4) involving family/key persons in care and psychoeducation of the patient, assuming the patient agrees to this; (5) ensuring optimal effectiveness of care; and (6) ensuring continuity in the care of patients with schizophrenia. The application of these six principles should help to raise awareness of and address poor patient adherence, as well as generally improving care of patients with schizophrenia. In turn, this should lead to improved overall clinical outcomes for patients receiving long-term treatment for schizophrenia.
引用
收藏
页码:97 / 107
页数:11
相关论文
共 92 条
  • [51] Medication adherence in schizophrenia: Exploring patients', carers' and professionals' views
    Kikkert, Martijn J.
    Schene, Aart H.
    Koeter, Maarten W. J.
    Robson, Debbie
    Born, Anja
    Helm, Hedda
    Nose, Michela
    Goss, Claudia
    Thornicroft, Graham
    Gray, Richard J.
    [J]. SCHIZOPHRENIA BULLETIN, 2006, 32 (04) : 786 - 794
  • [52] Importance of specialisation in psychiatric services
    Killaspy, Helen
    [J]. PSYCHIATRIC BULLETIN, 2012, 36 (10): : 364 - 365
  • [53] Non-adherence to antipsychotic medication regimens: associations with resource use and costs
    Knapp, M
    King, D
    Pugner, K
    Lapuerta, P
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 2004, 184 : 509 - 516
  • [54] Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: A comprehensive review of recent literature
    Lacro, JP
    Dunn, LB
    Dolder, CR
    Leckband, SG
    Jeste, DV
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2002, 63 (10) : 892 - 909
  • [55] The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations 2003
    Lehman, AF
    Kreyenbuhl, J
    Buchanan, RW
    Dickerson, FB
    Dixon, LB
    Goldberg, R
    Green-Paden, LD
    Tenhula, WN
    Boerescu, D
    Tek, C
    Sandson, N
    Steinwachs, DM
    [J]. SCHIZOPHRENIA BULLETIN, 2004, 30 (02) : 193 - 217
  • [56] Oral versus depot antipsychotic drugs for schizophrenia A critical systematic review and meta-analysis of randomised long-term trials
    Leucht, Claudia
    Heres, Stephan
    Kane, John M.
    Kissling, Werner
    Davis, John M.
    Leucht, Stefan
    [J]. SCHIZOPHRENIA RESEARCH, 2011, 127 (1-3) : 83 - 92
  • [57] Leucht S, 2006, J CLIN PSYCHIAT, V67, P3
  • [58] Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
    Leucht, Stefan
    Corves, Caroline
    Arbter, Dieter
    Engel, Rolf R.
    Li, Chunbo
    Davis, John M.
    [J]. LANCET, 2009, 373 (9657) : 31 - 41
  • [59] Lieberman JA, 1996, J CLIN PSYCHIAT, V57, P5
  • [60] Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    Lieberman, JA
    Stroup, TS
    McEvoy, JP
    Swartz, MS
    Rosenheck, RA
    Perkins, DO
    Keefe, RSE
    Davis, SM
    Davis, CE
    Lebowitz, BD
    Severe, J
    Hsiao, JK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (12) : 1209 - 1223